Trial Profile
An Open-label, Multi-center, Rollover Study in Patients With Advanced Melanoma After Completing an IMCgp100 Clinical Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Tebentafusp (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Immunocore
- 29 May 2019 Status changed from active, no longer recruiting to discontinued.
- 19 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.